References
- Horning SJ, Hoppe RT, Breslin S, et al Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630–637.
- Meyer RM, Gospodarowicz MK, Connors JM, et al Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634–4642.
- Adams MJ, Lipsitz SR, Colan SD, et al Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004;22:3139–3148.
- Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–1886.
- Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin's lymphoma treated with radiation therapy. JAMA 2003;290:2831–2837.
- Pinarli FG, Oguz A, Tunaoglu FS, et al Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005;44:370–377.
- Salloum E, Tanoue LT, Wackers FJ, et al Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. Cancer Invest 1999;17:171–180.
- Myrehaug S, Pintilie M, Tsang R, et al Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486–1493.
- Bonadonna G, Bonfante V, Viviani S, et al ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004;22:2835–2841.
- Campbell BA, Voss N, Pickles T, et al Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol 2008;26:5170–5174.
- Engert A, Schiller P, Josting A, et al Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601–3608.
- Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 2001;49:1429–1438.
- Hudson MM, Rai SN, Nunez C, et al Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007;25:3635–3643.
- Engert A, Diehl V, Pluetschow A, et al Two cycles of ABVD followed by involved field radiotherapy with 20 gray (Gy) is the new standard of care in the treatment of patients with early-stage Hodgkin Lymphoma: final analysis of the randomized German Hodgkin Study Group (GHSG) HD10. Blood 2009;114(Suppl. 1): 114 (Abstract 716).
- Chera BS, Rodriguez C, Morris CG, et al Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 2009;75:1173–1180.
- Schneider U, Lomax A, Lombriser N. Comparative risk assessment of secondary cancer incidence after treatment of Hodgkin's disease with photon and proton radiation. Radiat Res 2000;154:382–388.